TY - JOUR
T1 - Advances in glaucoma therapy
T2 - Brimonidine tartrate
AU - Greenfield, David S.
AU - Liebmann, Jeffrey M.
AU - Ritch, Robert
N1 - Funding Information:
From the Departments of 'Ophthalmology and 2Neurology, New York Eye and Ear Infirmary, New York, NX and New York Medical College, Valhalla, NK Supported in part by the New York Glaucoma Research Institute, New York, NK The authors have no proprietary interest in Allergan Inc, brimonidine, or any of the pharmaceutical products described in this manuscript. DI: Liebmann has been a consultant to Allergan, lnc.
PY - 1997
Y1 - 1997
N2 - Brimonidine, a newly approved α2-adrenoceptor agonist, is a 2- imidazoline derivative which is more highly selective for the α2- adrenoceptor than either clonidine or apraclonidine. The mechanism of action by which it lowers intraocular pressure (IOP) involves a decrease in aqueous humor production and an increase in aqueous humor outflow through the uveoscleral pathway. Clinical studies have been performed for acute indications using the 0.5% concentration and chronic indications using the 0.2% concentration. This review discusses the mechanism of action, efficacy, and safety of this new compound.
AB - Brimonidine, a newly approved α2-adrenoceptor agonist, is a 2- imidazoline derivative which is more highly selective for the α2- adrenoceptor than either clonidine or apraclonidine. The mechanism of action by which it lowers intraocular pressure (IOP) involves a decrease in aqueous humor production and an increase in aqueous humor outflow through the uveoscleral pathway. Clinical studies have been performed for acute indications using the 0.5% concentration and chronic indications using the 0.2% concentration. This review discusses the mechanism of action, efficacy, and safety of this new compound.
UR - http://www.scopus.com/inward/record.url?scp=0030756617&partnerID=8YFLogxK
U2 - 10.3109/08820539709059809
DO - 10.3109/08820539709059809
M3 - Article
AN - SCOPUS:0030756617
SN - 0882-0538
VL - 12
SP - 127
EP - 133
JO - Seminars in Ophthalmology
JF - Seminars in Ophthalmology
IS - 3
ER -